Executing Bridging Studies When Changing Analytical Methods During Clinical Trials

Introduction: Why Analytical Method Changes Require Bridging Studies

In long-duration or multi-phase clinical trials, sponsors may find it necessary to change or upgrade the bioanalytical method used to analyze biological samples. These changes may be driven by improved assay sensitivity, revised biomarker panels, lab transitions, or regulatory updates. However, such transitions raise critical questions about data continuity and comparability.

Bridging studies are essential to demonstrate that the new analytical method generates results comparable to the old method, ensuring the integrity of trial data and avoiding regulatory concerns. Without such studies, changes in analytical methods may lead to inconsistencies that compromise primary endpoints and affect submission acceptance by agencies such as the FDA, EMA, and PMDA.

Regulatory Guidance on Method Transitions

Both the FDA and EMA have established expectations for method bridging during trials. These are elaborated in:

• FDA’s Bioanalytical Method Validation Guidance (2018): Requires cross-validation when analytical methods are modified mid-study.
• EMA Guideline on Bioanalytical Method Validation: Highlights the need for statistical comparison when methods differ across study phases or labs.
• ICH M10 Guideline (Draft): Offers a harmonized global framework for method validation, including bridging studies.

The key principle across all guidance is demonstrating that data generated before and after the method change are scientifically comparable and interchangeable.

Scenarios Requiring Bridging Studies

Bridging studies are necessary under the following scenarios:

• Transitioning from a manual ELISA to an automated immunoassay platform
• Switching from LC-MS/MS to high-resolution MS-based quantification
• Changing detection kits or reagents from one vendor to another
• Transferring methods from one central lab to another
• Adding new matrix types (e.g., switching from plasma to serum)

Even seemingly minor changes (e.g., modified sample extraction procedures, altered stability protocols) may trigger the requirement for bridging validation.

Designing a Bridging Study Protocol

Bridging studies should be pre-defined in a standalone protocol or an addendum to the original method validation plan. Key design elements include:

• Sample Set: Typically 20–50 clinical samples spanning the analytical range
• Replicate Analysis: Each sample should be tested using both the old and new method under controlled conditions
• Acceptance Criteria: Pre-specified agreement thresholds (e.g., 85–115% accuracy, ±15% CV for precision)
• Statistical Tests: Bland-Altman plots, Deming regression, Passing-Bablok regression, correlation coefficients
• Documentation: Bridging report with conclusions about method comparability

Agencies may require submission of the full bridging study during NDA/BLA filing or may request access during inspections.

Sample Bridging Study Outcome Table

Average bias: ±1.5% — within acceptable limits. Conclusion: Methods are comparable.

Inspection-Ready Documentation Requirements

Bridging studies are subject to inspection by regulatory agencies. To be inspection-ready, sponsors should maintain:

• Change control logs and rationale for method change
• Bridging study protocol and approval records
• Raw data and chromatograms/plate reads from both methods
• Statistical analysis reports and audit trails
• CAPA plans if method variability exceeds acceptance thresholds

CAPA Strategies for Bridging Failures

If the new method fails to demonstrate equivalency with the previous method, the following CAPA actions may be considered:

• Root Cause Analysis: Determine if variability is due to instrumentation, sample degradation, or operator errors
• Corrective Measures: Repeat bridging with tighter SOP adherence or modified sample prep
• Preventive Actions: Enhance SOPs to require prior feasibility studies before method rollout
• Data Impact Analysis: Assess which samples or subjects may need retesting or exclusion

SOP Requirements for Bridging Studies

A dedicated SOP should cover:

• Triggers for requiring a bridging study
• Roles and responsibilities for assay scientists, QA, and project managers
• Statistical methods for comparing datasets
• Reporting templates and required documentation

SOPs must be version-controlled and cross-referenced with quality management systems.

Case Example: Global Vaccine Study Method Transition

A global vaccine sponsor transitioned its immunogenicity assay from a manual ELISA to a multiplexed platform. After observing assay drift in initial validation, a bridging study was implemented using 40 historical and 40 fresh clinical samples.

Results demonstrated 93% agreement within ±10%, and a pre-submission meeting with the FDA confirmed that the transition could proceed with inclusion of the bridging report in the BLA dossier.

Conclusion: Risk-Based Approach to Analytical Method Changes

Changing analytical methods mid-trial is often necessary but must be managed through scientifically sound and regulatory-compliant bridging studies. These studies ensure that data remains valid, comparable, and suitable for pooled analysis.

By incorporating robust statistical methods, SOP governance, QA oversight, and CAPA readiness, sponsors can navigate method transitions without compromising clinical trial outcomes or regulatory approvals.